Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05124236
Other study ID # 410.000.146
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 29, 2022
Est. completion date December 30, 2025

Study information

Verified date September 2022
Source Kantonsspital Aarau
Contact Susanne Rogers, MD PhD
Phone +41 62 838 5726
Email Susanne.rogers@ksa.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The research question is whether a single fraction of preoperative radiosurgery can reduce the incidence of leptomeningeal disease 12 months following resection of a brain metastasis (BM) as compared with 5 fractions of postoperative stereotactic radiotherapy.


Description:

Neurosurgical resection of a brain metastasis in patients with a diagnosis of cancer may be indicated however the recurrence rate approximates 50% and adjuvant radiotherapy is standard. Single fraction postoperative stereotactic radiosurgery (SRS) has been widely adopted as a standard therapy as it achieves equivalent survival and prevents loss of neurocognitive function as compared with whole brain radiotherapy and improves cavity local control rates as compared with observation. Hypofractionated stereotactic radiotherapy in 3 to 5 fractions (hfSRT) is also used in the postoperative setting. Nodular leptomeningeal disease (nLMD) is a recognised pattern of failure after postoperative SRS and hfSRT. A 16.9% incidence of nodular LMD was seen after surgery and a similar incidence of 11%-28%is reported following postoperative SRS in retrospective series. These data suggest that postoperative SRS/hfSRT have no significant effect on the development of LMD following surgery. The incidence of LMD following single fraction preoperative SRS is only 6.1% according to the largest retrospective series. Preoperative SRS takes advantage of the easier delineation of an intact BM and sterilizes tumor cells disseminated at surgery. Side effects are minimized by a smaller planning margin, a dose reduction and resection of the irradiated volume. In addition, there is no delay to systemic therapy due to wound healing/complications. Furthermore, a single fraction offers patient convenience. This trial will randomise and compare intracranial outcomes between single fraction preoperative SRS and 5 fraction postoperative hFSRT.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date December 30, 2025
Est. primary completion date December 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Age =18 4. Karnofsky performance status =60 5. Histological diagnosis of a malignant primary or metastatic tumour 6. Ability to take steroids 7. No contraindication to magnetic resonance imaging (MRI) 8. MRI-diagnosis of a clearly demarcated contrast-enhancing brain metastasis up to 4.0 cm diameter indicated for neurosurgical resection (tumorboard decision). Up to 3 other brain metastases suitable for primary radiosurgery/ stereotactic radiotherapy 9. Survival estimated by primary clinician > 12 months 10. Platelet count > 100/ml, INR < 1.3, Hb > 7.5 g/dL Exclusion Criteria: 1. Radiosensitive histology: germ cell tumour, lymphoma, multiple myeloma 2. >10 mm midline shift, effacement of the 4th ventricle or other sign of raised intracranial pressure requiring urgent decompressive surgery 3. More than 4 brain metastases or the diameter of the metastasis for resection >4.0 cm. 4. More than 1 metastasis requiring resection 5. Leptomeningeal disease in the CSF or on MRI (unless localized and can be irradiated then resected with the metastasis) 6. Prior radiation to the brain (SRS/SRT to lesion to be resected and /or WBRT) 7. Prior resection of a primary or secondary brain tumor 8. Prior diagnosis of a non-meningioma brain tumor 9. Prior radionuclide therapy within 30 days 10. Prior anti-VEGF therapy within 6 weeks 11. Unable to tolerate radiosurgery immobilization and treatment 12. Inability to give informed consent 13. Pregnancy or lactation 14. Females of reproductive potential not willing to use effective contraception for at least 6 months after radiotherapy 15. Males of reproductive potential not effective contraception for 3 months after radiotherapy 16. Lack of likely compliance with protocol and follow-up

Study Design


Intervention

Radiation:
preoperative radiosurgery
single fraction radiosurgery
postoperative hypofractionated stereotactic radiotherapy
5 fraction stereotactic radiotherapy /fractionated radiosurgery

Locations

Country Name City State
Switzerland Kantonsspital Aarau Aarau Aargau
Switzerland Inselspital, Universitätsklinik für Radio-Onkologie Bern Freiburgstrasse
Switzerland Kantonsspital Graubünden Chur
Switzerland Luzerner Kantonsspital Luzern
Switzerland Kantonsspital St. Gallen St. Gallen
Switzerland Kantonsspital Winterthur Winterthur

Sponsors (3)

Lead Sponsor Collaborator
Susanne Rogers Technische Universität München, University of Basel

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Leptomeningeal disease Incidence (%) 12 months after intervention
Secondary Local control of the surgical cavity No evidence of tumour recurrence on contrsat-enhanced MRI 12 months after intervention
Secondary Distant brain failure New brain metastases 12 months after intervention
Secondary Radionecrosis Adverse radiation effects 12 months after intervention
Secondary Quality of life assessment EORTC questionnaire core questionnaire QLQ30, EORTC questionnaire brain module BN 20 (1-4, low scores reflect better QoL) 3,6,12 months after intervention
See also
  Status Clinical Trial Phase
Recruiting NCT05428852 - Keto-Brain:Investigating the Use of Ketogenic Diets in Brain Metastases N/A
Recruiting NCT05559853 - Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
Recruiting NCT05689619 - SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET) N/A
Recruiting NCT04197297 - Brain Imaging Biomarkers in Patients With Brain Metastasis Phase 2
Recruiting NCT04397978 - Local Ablative Therapy for Patients With Multiple (4-10) Brain Metastases
Terminated NCT04434560 - Neoadjuvant Immunotherapy in Brain Metastases Phase 2
Active, not recruiting NCT05095766 - Comparaison Between MRI Alone or Combined With Positron Emission Tomography for Brain Metastasis Diagnosis
Recruiting NCT05012254 - Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases Phase 2
Recruiting NCT05789589 - Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases Phase 1/Phase 2
Recruiting NCT06280300 - Multi-disciplinary Care for Brain Metastases N/A
Recruiting NCT06047379 - Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis Phase 1/Phase 2
Completed NCT03896555 - Intrafractional Head Movement During Radiosurgery
Terminated NCT03789149 - Focal Intraoperative Radiotherapy of Brain Metastases Phase 2
Recruiting NCT04343157 - UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases Phase 2
Recruiting NCT04711824 - Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases Phase 1/Phase 2
Recruiting NCT05793489 - Prospective Double Arm Randomized Trial: WBRT Alone and WBRT Plus Silibinin N/A
Recruiting NCT04461418 - Accelerated Checkpoint Therapy for Any Steroid Dependent Patient With Brain Metastases Phase 2
Active, not recruiting NCT03818386 - Radiotherapy of Multiple Brain Metastases Using AGuIX® Phase 2
Active, not recruiting NCT05087095 - Managing Distress in Malignant Brain Cancer N/A
Recruiting NCT04396717 - Safety Study of Pritumumab in Brain Cancer Phase 1